← All trials
NCT07230574
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2025
- Primary completion
- Sep 30, 2028
- Completion date
- Sep 30, 2028
- First posted
- Nov 17, 2025
- Last posted
- Nov 17, 2025
- Enrollment
- 159
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nanjing UniversityLead sponsor
- Soochow UniversityCollaborator
- University of Science and Technology of ChinaCollaborator
- University of Science and Technology of ChinaCollaborator
- Nanjing UniversitySponsor investigator
- Anhui Medical UniversityCollaborator
- Nanjing UniversityOfficial
- Zhejiang UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.